Skip to main content

Advertisement

SpringerLink
Log in

Other types of diffuse liver disease: is there a way to do it?

  • Special Section: Diffuse Liver Disease
  • Published:
Abdominal Radiology Aims and scope Submit manuscript

Abstract

There are a variety of less common diffuse liver diseases that can be asymptomatic or cause severe liver dysfunction. For the majority of them, the association of clinical, laboratory, and imaging findings are needed to narrow the differential diagnosis. In this article, we will review and describe the rarer diffuse liver diseases including drug-related liver disease, inflammatory and infectious diseases, and deposition disorders such as amyloidosis, glycogen storage disease, Wilson’s disease, and alpha-1 antitrypsin deficiency. Abdominal radiologists should be familiar with the imaging features of different types of diffuse liver diseases to help the multidisciplinary team involved in the treatment of these patients. The data related to some of these conditions are scarce and sometimes experimental, but we want to demonstrate to the reader the value of imaging techniques in their analysis and introduce the potential of new imaging methods.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13
Fig. 14
Fig. 15

Similar content being viewed by others

References

  1. Bastati N, Beer L, Mandorfer M, Poetter-Lang S, Tamandl D, Bican Y, et al. Does the Functional Liver Imaging Score Derived from Gadoxetic Acid-enhanced MRI Predict Outcomes in Chronic Liver Disease? Radiology. 2020;294(1):98-107.

    Article  PubMed  Google Scholar 

  2. Ba-Ssalamah A, Bastati N, Wibmer A, Fragner R, Hodge JC, Trauner M, et al. Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we? J Magn Reson Imaging. 2017;45(3):646-59.

    Article  PubMed  Google Scholar 

  3. Beer L, Mandorfer M, Bastati N, Poetter-Lang S, Tamandl D, Stoyanova DP, et al. Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases. Eur Radiol. 2019;29(12):6600-10.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Ngo D, Jia JB, Green CS, Gulati AT, Lall C. Cancer therapy related complications in the liver, pancreas, and biliary system: an imaging perspective. Insights Imaging. 2015;6(6):665-77.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354(7):731-9.

    Article  CAS  PubMed  Google Scholar 

  6. Navarro F, Le Moine MC, Fabre JM, Belghiti J, Cherqui D, Adam R, et al. Specific vascular complications of orthotopic liver transplantation with preservation of the retrohepatic vena cava: review of 1361 cases. Transplantation. 1999;68(5):646-50.

    Article  CAS  PubMed  Google Scholar 

  7. Sharma A, Houshyar R, Bhosale P, Choi JI, Gulati R, Lall C. Chemotherapy induced liver abnormalities: an imaging perspective. Clin Mol Hepatol. 2014;20(3):317-26.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Alessandrino F, Tirumani SH, Krajewski KM, Shinagare AB, Jagannathan JP, Ramaiya NH, et al. Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors. Clin Radiol. 2017;72(7):521-33.

    Article  CAS  PubMed  Google Scholar 

  9. Vernuccio F, Dioguardi Burgio M, Barbiera F, Cusmà S, Badalamenti G, Midiri M, et al. CT and MR imaging of chemotherapy-induced hepatopathy. Abdom Radiol (NY). 2019;44(10):3312-24.

    Article  PubMed  Google Scholar 

  10. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg. 2005;200(6):845-53.

    Article  PubMed  Google Scholar 

  11. Ramadori G, Cameron S. Effects of systemic chemotherapy on the liver. Ann Hepatol. 2010;9(2):133-43.

    Article  CAS  PubMed  Google Scholar 

  12. Berger-Kulemann V, Schima W, Baroud S, Koelblinger C, Kaczirek K, Gruenberger T, et al. Gadoxetic acid-enhanced 3.0 T MR imaging versus multidetector-row CT in the detection of colorectal metastases in fatty liver using intraoperative ultrasound and histopathology as a standard of reference. Eur J Surg Oncol. 2012;38(8):670-6.

  13. Wibmer A, Prusa AM, Nolz R, Gruenberger T, Schindl M, Ba-Ssalamah A. Liver failure after major liver resection: risk assessment by using preoperative Gadoxetic acid-enhanced 3-T MR imaging. Radiology. 2013;269(3):777-86.

    Article  PubMed  Google Scholar 

  14. Adler M, Tang I, Gach MW, MacFaul G. Recurrent metastatic breast cancer presenting with portal hypertension and pseudocirrhosis. BMJ Case Rep. 2019;12(11).

  15. Vuppalanchi R, Saxena R, Storniolo AMV, Chalasani N. Pseudocirrhosis and liver failure in patients with metastatic breast cancer after treatment with palbociclib. Hepatology. 2017;65(5):1762-4.

    Article  PubMed  Google Scholar 

  16. Jeong WK, Choi SY, Kim J. Pseudocirrhosis as a complication after chemotherapy for hepatic metastasis from breast cancer. Clin Mol Hepatol. 2013;19(2):190-4.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Leshchinskiy S, Kanner C, Keating DP. Pseudocirrhosis. Abdom Radiol (NY). 2018;43(11):3197-8.

    Article  PubMed  Google Scholar 

  18. Adike A, Karlin N, Menias C, Carey EJ. Pseudocirrhosis: A Case Series and Literature Review. Case Rep Gastroenterol. 2016;10(2):381-91.

    Article  PubMed  PubMed Central  Google Scholar 

  19. DeLeve L, Kaplowitz N. Drug-Induced Liver Disease2002.

  20. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15(3):460-6.

    Article  CAS  PubMed  Google Scholar 

  21. Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Pathak P, et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 2010;28(15):2549-55.

    Article  CAS  PubMed  Google Scholar 

  22. Harris L, McKenna WJ, Rowland E, Holt DW, Storey GC, Krikler DM. Side effects of long-term amiodarone therapy. Circulation. 1983;67(1):45-51.

    Article  CAS  PubMed  Google Scholar 

  23. Markos J, Veronese ME, Nicholson MR, McLean S, Shevland JE. Value of hepatic computerized tomographic scanning during amiodarone therapy. Am J Cardiol. 1985;56(1):89-92.

    Article  CAS  PubMed  Google Scholar 

  24. Matsuda M, Otaka A, Tozawa T, Asano T, Ishiyama K, Hashimoto M. Analysis of computed tomography density of liver before and after amiodarone administration. Jpn J Radiol. 2018;36(5):340-4.

    Article  PubMed  Google Scholar 

  25. Kojima S, Ueno H, Takeya M, Ogawa H. Increased density of the liver and amiodarone-associated phospholipidosis. Cardiol Res Pract. 2009;2009:598940.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Suzuki H, Imafuji A, Kato M, Omiya H. Dual Energy CT Assessment of Amiodarone Induced Liver Damage. Somatom Sessions2014. p. 64-5.

  27. Guigui B, Perrot S, Berry JP, Fleury-Feith J, Martin N, Métreau JM, et al. Amiodarone-induced hepatic phospholipidosis: a morphological alteration independent of pseudoalcoholic liver disease. Hepatology. 1988;8(5):1063-8.

    Article  CAS  PubMed  Google Scholar 

  28. Hussain N, Bhattacharyya A, Prueksaritanond S. Amiodarone-induced cirrhosis of liver: what predicts mortality? ISRN Cardiol. 2013;2013:617943.

    PubMed  PubMed Central  Google Scholar 

  29. Buggey J, Kappus M, Lagoo AS, Brady CW. Amiodarone-Induced Liver Injury and Cirrhosis. ACG Case Rep J. 2015;2(2):116-8.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Bartalena T, Rinaldi MF. Hyperdense spleen after prolonged gold therapy. CMAJ. 2010;182(18):E858.

    Article  PubMed  PubMed Central  Google Scholar 

  31. De Maria M, De Simone G, Laconi A, Mercadante G, Pavone P, Rossi P. Gold storage in the liver: appearance on CT scans. Radiology. 1986;159(2):355-6.

    Article  PubMed  Google Scholar 

  32. Bluhbaum T, Frik K, Kalkbrenner H. Eine neuve Anwendungsart der Kolloide in der Rontgendiagnostik. ROFO1928. p. 18-29.

  33. Silverman PM, Ram PC, Korobkin M. CT appearance of abdominal thorotrast deposition and Thorotrast-induced angiosarcoma of the liver. J Comput Assist Tomogr. 1983;7(4):655-8.

    Article  CAS  PubMed  Google Scholar 

  34. Macmahon HE, Murphy AS, Bates MI. Endothelial-Cell Sarcoma of Liver Following Thorotrast Injections. Am J Pathol. 1947;23(4):585-611.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Kiyosawa K, Akahane Y, Miyazaki Y, Sato K, Shirai T, Mizuno T, et al. Resection of thorotrast-induced cholangiocarcinoma. Am J Gastroenterol. 1983;78(7):429-33.

    CAS  PubMed  Google Scholar 

  36. Ito Y, Kojiro M, Nakashima T, Mori T. Pathomorphologic characteristics of 102 cases of thorotrast-related hepatocellular carcinoma, cholangiocarcinoma, and hepatic angiosarcoma. Cancer. 1988;62(6):1153-62.

    Article  CAS  PubMed  Google Scholar 

  37. Stojkovic M, Müller J, Junghanss T, Weber TF. Radiological Diagnoses in the Context of Emigration: Infectious diseases. Rofo. 2018;190(2):121-33.

    Article  PubMed  Google Scholar 

  38. Mergo PJ, Ros PR, Buetow PC, Buck JL. Diffuse disease of the liver: radiologic-pathologic correlation. Radiographics. 1994;14(6):1291-307.

    Article  CAS  PubMed  Google Scholar 

  39. Mortelé KJ, Segatto E, Ros PR. The infected liver: radiologic-pathologic correlation. Radiographics. 2004;24(4):937-55.

    Article  PubMed  Google Scholar 

  40. Toda KS, Kikuchi L, Chagas AL, Tanigawa RY, Paranaguá-Vezozzo DC, Pfiffer T, et al. Hepatocellular Carcinoma Related to Schistosoma mansoni Infection: Case Series and Literature Review. J Clin Transl Hepatol. 2015;3(4):260-4.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Bilgin SS, Toprak H, Seker M. Imaging findings of hepatosplenic schistosomiasis: a case report. Radiol Case Rep. 2016;11(3):152-6.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Cerri GG, Alves VA, Magalhães A. Hepatosplenic schistosomiasis mansoni: ultrasound manifestations. Radiology. 1984;153(3):777-80.

    Article  CAS  PubMed  Google Scholar 

  43. Mamone G, Cortis K, Sarah A, Caruso S, Miraglia R. Hepatic morphology abnormalities: beyond cirrhosis. Abdom Radiol (NY). 2018;43(7):1612-26.

    Article  PubMed  Google Scholar 

  44. Bezerra AS, D’Ippolito G, Caldana RP, Leopoldino DD, Batista GR, Borges DR, et al. Differentiating cirrhosis and chronic hepatosplenic schistosomiasis using MRI. AJR Am J Roentgenol. 2008;190(3):W201-7.

    Article  PubMed  Google Scholar 

  45. Olveda DU, Olveda RM, Lam AK, Chau TN, Li Y, Gisparil AD, et al. Utility of Diagnostic Imaging in the Diagnosis and Management of Schistosomiasis. Clin Microbiol. 2014;3(2).

  46. Fetzer DT, Rees MA, Dasyam AK, Tublin ME. Hepatic sarcoidosis in patients presenting with liver dysfunction: imaging appearance, pathological correlation and disease evolution. Eur Radiol. 2016;26(9):3129-37.

    Article  PubMed  Google Scholar 

  47. Tana C, Schiavone C, Ticinesi A, Ricci F, Giamberardino MA, Cipollone F, et al. Ultrasound imaging of abdominal sarcoidosis: State of the art. World J Clin Cases. 2019;7(7):809-18.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Masuda K, Takenaga S, Morikawa K, Kano A, Ojiri H. Hepatic sarcoidosis with atypical radiological manifestations: A case report. Radiol Case Rep. 2018;13(5):936-9.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Peters B, Vanhoenacker FM, Bernard P, Van Dijck H, Van Overbeke L. Hepatosplenic Sarcoidosis Complicated by Liver Cirrhosis. J Belg Soc Radiol. 2015;99(2):53-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Palmucci S, Torrisi SE, Caltabiano DC, Puglisi S, Lentini V, Grassedonio E, et al. Clinical and radiological features of extra-pulmonary sarcoidosis: a pictorial essay. Insights Imaging. 2016;7(4):571-87.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Ch’ng LS, Amzar H, Ghazali KC, Siam F. Imaging appearances of hepatic tuberculosis: experience with 12 patients. Clin Radiol. 2018;73(3):321.e11-.e16.

  52. Schininà V, Albarello F, Cristofaro M, Di Stefano F, Fusco N, Cuzzi G, et al. Diagnostic imaging of hepatic tuberculosis: case series. Int J Tuberc Lung Dis. 2018;22(7):779-87.

    Article  PubMed  Google Scholar 

  53. Deshpande SS, Joshi AR, Phajlani SA. Computed tomographic features of abdominal tuberculosis: unmask the impersonator! Abdom Radiol (NY). 2019;44(1):11-21.

    Article  PubMed  Google Scholar 

  54. Yu RS, Zhang SZ, Wu JJ, Li RF. Imaging diagnosis of 12 patients with hepatic tuberculosis. World J Gastroenterol. 2004;10(11):1639-42.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Indiran V, Vinoth Kumar R. ‘Frosted liver’ appearance. Abdom Radiol (NY). 2017;42(10):2587.

    Article  PubMed  Google Scholar 

  56. Jain N, Rissam HK, Puri SK, Chauhan U. The “frosted liver” appearance in hepatic tuberculosis: a rare presentation. BJR Case Rep. 2016;2(4):20150367.

    PubMed  PubMed Central  Google Scholar 

  57. Kakkar C, Polnaya AM, Koteshwara P, Smiti S, Rajagopal KV, Arora A. Hepatic tuberculosis: a multimodality imaging review. Insights Imaging. 2015;6(6):647-58.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Doppman JL, Cornblath M, Dwyer AJ, Adams AJ, Girton ME, Sidbury J. Computed tomography of the liver and kidneys in glycogen storage disease. J Comput Assist Tomogr. 1982;6(1):67-71.

    Article  CAS  PubMed  Google Scholar 

  59. Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics. 2000;105(1):e10.

    Article  CAS  PubMed  Google Scholar 

  60. Shin YS. Glycogen storage disease: clinical, biochemical, and molecular heterogeneity. Semin Pediatr Neurol. 2006;13(2):115-20.

    Article  PubMed  Google Scholar 

  61. Labrune P, Trioche P, Duvaltier I, Chevalier P, Odièvre M. Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. J Pediatr Gastroenterol Nutr. 1997;24(3):276-9.

    Article  CAS  PubMed  Google Scholar 

  62. Ozen H. Glycogen storage diseases: new perspectives. World J Gastroenterol. 2007;13(18):2541-53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Oterdoom LH, Verweij KE, Biermann K, Langeveld M, van Buuren HR. Hepatocellular Adenomas and Carcinoma in Asymptomatic, Non-Cirrhotic Type III Glycogen Storage Disease. J Gastrointestin Liver Dis. 2015;24(4):515-8.

    Article  PubMed  Google Scholar 

  64. Iijima H, Moriwaki Y, Yamamoto T, Takahashi S, Nishigami T, Hada T. Spontaneous regression of hepatic adenoma in a patient with glycogen storage disease type I after hemodialysis: ultrasonographic and CT findings. Intern Med. 2001;40(9):891-5.

    Article  CAS  PubMed  Google Scholar 

  65. Sherigar JM, Castro J, Yin YM, Guss D, Mohanty SR. Glycogenic hepatopathy: A narrative review. World J Hepatol. 2018;10(2):172-85.

    Article  PubMed  PubMed Central  Google Scholar 

  66. MacDonald MJ, Hasan NM, Ansari IU, Longacre MJ, Kendrick MA, Stoker SW. Discovery of a Genetic Metabolic Cause for Mauriac Syndrome in Type 1 Diabetes. Diabetes. 2016;65(7):2051-9.

    Article  CAS  PubMed  Google Scholar 

  67. Sweetser S, Kraichely RE. The bright liver of glycogenic hepatopathy. Hepatology. 2010;51(2):711-2.

    Article  PubMed  Google Scholar 

  68. Murata F, Horie I, Ando T, Isomoto E, Hayashi H, Akazawa S, et al. A case of glycogenic hepatopathy developed in a patient with new-onset fulminant type 1 diabetes: the role of image modalities in diagnosing hepatic glycogen deposition including gradient-dual-echo MRI. Endocr J. 2012;59(8):669-76.

    Article  PubMed  Google Scholar 

  69. Longo R, Pollesello P, Ricci C, Masutti F, Kvam BJ, Bercich L, et al. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging. 1995;5(3):281-5.

    Article  CAS  PubMed  Google Scholar 

  70. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005;288(2):E462-8.

    Article  CAS  PubMed  Google Scholar 

  71. Qayyum A. MR spectroscopy of the liver: principles and clinical applications. Radiographics. 2009;29(6):1653-64.

    Article  PubMed  Google Scholar 

  72. Machann J, Stefan N, Schick F. (1)H MR spectroscopy of skeletal muscle, liver and bone marrow. Eur J Radiol. 2008;67(2):275-84.

    Article  PubMed  Google Scholar 

  73. Ouwerkerk R, Pettigrew RI, Gharib AM. Liver metabolite concentrations measured with 1H MR spectroscopy. Radiology. 2012;265(2):565-75.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Hwang JH, Choi CS. Use of in vivo magnetic resonance spectroscopy for studying metabolic diseases. Exp Mol Med. 2015;47:e139.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Roser W, Beckmann N, Wiesmann U, Seelig J. Absolute quantification of the hepatic glycogen content in a patient with glycogen storage disease by 13C magnetic resonance spectroscopy. Magn Reson Imaging. 1996;14(10):1217-20.

    Article  CAS  PubMed  Google Scholar 

  76. Kishore P, Gabriely I, Cui MH, Di Vito J, Gajavelli S, Hwang JH, et al. Role of hepatic glycogen breakdown in defective counterregulation of hypoglycemia in intensively treated type 1 diabetes. Diabetes. 2006;55(3):659-66.

    Article  CAS  PubMed  Google Scholar 

  77. Hwang JH, Perseghin G, Rothman DL, Cline GW, Magnusson I, Petersen KF, et al. Impaired net hepatic glycogen synthesis in insulin-dependent diabetic subjects during mixed meal ingestion. A 13C nuclear magnetic resonance spectroscopy study. J Clin Invest. 1995;95(2):783-7.

  78. Roden M, Perseghin G, Petersen KF, Hwang JH, Cline GW, Gerow K, et al. The roles of insulin and glucagon in the regulation of hepatic glycogen synthesis and turnover in humans. J Clin Invest. 1996;97(3):642-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Mishkovsky M, Comment A, Gruetter R. In vivo detection of brain Krebs cycle intermediate by hyperpolarized magnetic resonance. J Cereb Blood Flow Metab. 2012;32(12):2108-13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Jones KM, Pollard AC, Pagel MD. Clinical applications of chemical exchange saturation transfer (CEST) MRI. J Magn Reson Imaging. 2018;47(1):11-27.

    Article  PubMed  Google Scholar 

  81. Chen SZ, Yuan J, Deng M, Wei J, Zhou J, Wáng YX. Chemical exchange saturation transfer (CEST) MR technique for in-vivo liver imaging at 3.0 tesla. Eur Radiol. 2016;26(6):1792-800.

  82. Gitlin JD. Wilson disease. Gastroenterology. 2003;125(6):1868-77.

    Article  PubMed  Google Scholar 

  83. Tanzi RE, Petrukhin K, Chernov I, Pellequer JL, Wasco W, Ross B, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet. 1993;5(4):344-50.

    Article  CAS  PubMed  Google Scholar 

  84. Ala A, Schilsky ML. Wilson disease: pathophysiology, diagnosis, treatment, and screening. Clin Liver Dis. 2004;8(4):787-805, viii.

  85. Ferenci P, Caca K, Loudianos G, Mieli-Vergani G, Tanner S, Sternlieb I, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int. 2003;23(3):139-42.

    Article  PubMed  Google Scholar 

  86. Cheon JE, Kim IO, Seo JK, Ko JS, Lee JM, Shin CI, et al. Clinical application of liver MR imaging in Wilson’s disease. Korean J Radiol. 2010;11(6):665-72.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Akhan O, Akpinar E, Karcaaltincaba M, Haliloglu M, Akata D, Karaosmanoglu AD, et al. Imaging findings of liver involvement of Wilson’s disease. Eur J Radiol. 2009;69(1):147-55.

    Article  PubMed  Google Scholar 

  88. Boll DT, Merkle EM. Diffuse liver disease: strategies for hepatic CT and MR imaging. Radiographics. 2009;29(6):1591-614.

    Article  PubMed  Google Scholar 

  89. Fritzsch D, Reiss-Zimmermann M, Trampel R, Turner R, Hoffmann KT, Schäfer A. Seven-tesla magnetic resonance imaging in Wilson disease using quantitative susceptibility mapping for measurement of copper accumulation. Invest Radiol. 2014;49(5):299-306.

    Article  PubMed  Google Scholar 

  90. Unal E, Idilman IS, Karçaaltıncaba M. Multiparametric or practical quantitative liver MRI: towards millisecond, fat fraction, kilopascal and function era. Expert Rev Gastroenterol Hepatol. 2017;11(2):167-82.

    Article  CAS  PubMed  Google Scholar 

  91. Lachmann HJ, Hawkins PN. Systemic amyloidosis. Curr Opin Pharmacol. 2006;6(2):214-20.

    Article  CAS  PubMed  Google Scholar 

  92. Czeyda-Pommersheim F, Hwang M, Chen SS, Strollo D, Fuhrman C, Bhalla S. Amyloidosis: Modern Cross-sectional Imaging. Radiographics. 2015;35(5):1381-92.

    Article  PubMed  Google Scholar 

  93. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038):2641-54.

    Article  CAS  PubMed  Google Scholar 

  94. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, et al. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid. 2014;21(4):221-4.

    Article  PubMed  Google Scholar 

  95. Esplin BL, Gertz MA. Current trends in diagnosis and management of cardiac amyloidosis. Curr Probl Cardiol. 2013;38(2):53-96.

    Article  PubMed  Google Scholar 

  96. Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O’Fallon WM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79(7):1817-22.

    Article  CAS  PubMed  Google Scholar 

  97. Pinney JH, Smith CJ, Taube JB, Lachmann HJ, Venner CP, Gibbs SD, et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol. 2013;161(4):525-32.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Hemminki K, Li X, Försti A, Sundquist J, Sundquist K. Incidence and survival in non-hereditary amyloidosis in Sweden. BMC Public Health. 2012;12:974.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Monzawa S, Tsukamoto T, Omata K, Hosoda K, Araki T, Sugimura K. A case with primary amyloidosis of the liver and spleen: radiologic findings. Eur J Radiol. 2002;41(3):237-41.

    Article  PubMed  Google Scholar 

  100. Scott PP, Scott WW, Siegelman SS. Amyloidosis: an overview. Semin Roentgenol. 1986;21(2):103-12.

    Article  CAS  PubMed  Google Scholar 

  101. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112(13):2047-60.

    Article  PubMed  Google Scholar 

  102. Shin YM. Hepatic amyloidosis. Korean J Hepatol. 2011;17(1):80-3.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Gertz MA, Kyle RA. Hepatic amyloidosis: clinical appraisal in 77 patients. Hepatology. 1997;25(1):118-21.

    Article  CAS  PubMed  Google Scholar 

  104. Kim SH, Han JK, Lee KH, Won HJ, Kim KW, Kim JS, et al. Abdominal amyloidosis: spectrum of radiological findings. Clin Radiol. 2003;58(8):610-20.

    Article  CAS  PubMed  Google Scholar 

  105. Benson L, Hemmingsson A, Ericsson A, Jung B, Sperber G, Thuomas KA, et al. Magnetic resonance imaging in primary amyloidosis. Acta Radiol. 1987;28(1):13-5.

    Article  CAS  PubMed  Google Scholar 

  106. Møller JM, Santoni-Rugiu E, Chabanova E, Løgager V, Hansen AB, Thomsen HS. Magnetic resonance imaging with liver-specific contrast agent in primary amyloidosis and intrahepatic cholestasis. Acta Radiol. 2007;48(2):145-9.

    Article  PubMed  Google Scholar 

  107. Castaño A, Bokhari S, Brannagan TH, Wynn J, Maurer MS. Technetium pyrophosphate myocardial uptake and peripheral neuropathy in a rare variant of familial transthyretin (TTR) amyloidosis (Ser23Asn): a case report and literature review. Amyloid. 2012;19(1):41-6.

    Article  PubMed  CAS  Google Scholar 

  108. Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D, et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging. 2014;15(11):1289-98.

    Article  PubMed  Google Scholar 

  109. Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjö L, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2013;54(2):213-20.

    Article  CAS  PubMed  Google Scholar 

  110. Dorbala S, Vangala D, Semer J, Strader C, Bruyere JR, Di Carli MF, et al. Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging. 2014;41(9):1652-62.

    Article  CAS  PubMed  Google Scholar 

  111. Guillaud O, Dumortier J, Traclet J, Restier L, Joly P, Chapuis-Cellier C, et al. Assessment of liver fibrosis by transient elastography (Fibroscan. Clin Res Hepatol Gastroenterol. 2019;43(1):77-81.

    Article  PubMed  Google Scholar 

  112. Kim RG, Nguyen P, Bettencourt R, Dulai PS, Haufe W, Hooker J, et al. Magnetic resonance elastography identifies fibrosis in adults with alpha-1 antitrypsin deficiency liver disease: a prospective study. Aliment Pharmacol Ther. 2016;44(3):287-99.

    Article  CAS  PubMed  Google Scholar 

  113. Reiter R, Wetzel M, Hamesch K, Strnad P, Asbach P, Haas M, et al. Comparison of non-invasive assessment of liver fibrosis in patients with alpha1-antitrypsin deficiency using magnetic resonance elastography (MRE), acoustic radiation force impulse (ARFI) Quantification, and 2D-shear wave elastography (2D-SWE). PLoS One. 2018;13(4):e0196486.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  114. Hoy AM, Fallowfield JA. Editorial: non-invasive assessment of hepatic fibrosis in alpha-1 antitrypsin deficiency using magnetic resonance elastography. Aliment Pharmacol Ther. 2016;44(6):644-5.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to express their deepest gratitude to Andrei Purysko MD, from Abdominal Imaging and Nuclear Radiology Department, Cleveland Clinic, Cleveland OH, for providing cases of amyloidosis to this manuscript.

Funding

This research received no funding.

Author information

Authors and Affiliations

  1. Department of Radiology, University of Sao Paulo, Sao Paulo, Brazil

    Hilton Leao Filho & Natally Horvat

  2. Department of Radiology, Hospital Sírio-Libanês, Sao Paulo, Brazil

    Camila Vilela de Oliveira & Natally Horvat

  3. Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Dr. Ovídio Pires de Campos, 255, Cerqueira César, São Paulo, SP, 05403-000, Brazil

    Hilton Leao Filho

Authors
  1. Hilton Leao Filho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Camila Vilela de Oliveira
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Natally Horvat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hilton Leao Filho.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leao Filho, H., de Oliveira, C.V. & Horvat, N. Other types of diffuse liver disease: is there a way to do it?. Abdom Radiol 45, 3425–3443 (2020). https://doi.org/10.1007/s00261-020-02530-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-020-02530-6

Keywords

Search

Navigation